- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02850107
DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions (REALITY)
The REALITY Study: DiRectional AthErectomy + Drug-CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Des Moines, Iowa, United States, 50309
- Iowa Methodist Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 2135
- St. Elizabeth's
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Rex
-
-
Texas
-
Austin, Texas, United States, 78756
- Austin Heart
-
Longview, Texas, United States, 75605
- Longview Cardiac and Vascular Consultants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General Inclusion Criteria:
- Willing and able to provide informed consent;
- Age ≥ 18 years of age;
- Clinical evaluation determines Rutherford Category 2-4;
- Willing to comply with all study requirements;
- All lab work is within acceptable limits to undergo a percutaneous interventional procedure.
- Life expectancy, in the investigator's opinion, of at least 24 months.
Angiographic Inclusion Criteria:
- RVD ≥ 4mm and ≤ 7mm;
- Evidence of a ≥70% de novo or restenotic lesion or occlusion in the target lesion defined as in the superficial femoral artery and/or popliteal artery, located in the arterial segment starting at least 1 cm beyond the Common Femoral Artery (CFA) bifurcation between the superficial and profunda femoris arteries (proximal anatomical landmark) to the distal P2 segment of the popliteal artery;
Total lesion/occlusion length:
a. ≥ 8 cm and ≤ 18 cm
Total occlusion length
a. ≥ 6 cm and ≤10 cm
- Stenosis or occlusion begins 1cm below the profunda-SFA bifurcation;
- Femoral or popliteal stenosis or occlusion that does not extend beyond the P2 popliteal segment;
- Minimum 1 patent infrapopliteal vessel to the foot with ≤ 50% diameter stenosis;
- Grade 3 or 4 intimal, medial and/or mixed calcification per the PACSS as judged by the operator at the time of the procedure;
Index lesion fits within guidelines below:
9.1 If two lesions are ≤ 3 cm apart, treatment would be allowed as a single lesion providing they contain a segment of moderate or severe calcification and the total lesion length is ≥ 8 cm and ≤18 cm.
9.2 If more than one lesion is within the target vessel, and they are separated by > 3 cm of normal vessel, one lesion must be designated by the investigator as the target lesion as long as the lesion meets all angiographic eligibility criteria. Only one index lesion is permitted for analysis, but study will allow a second lesion to be treated as a non-target lesion.
- Infrapopliteal lesion, if diagnosed, can be staged and treated > 30 days after index procedure.
Exclusion Criteria:
General Exclusion Criteria:
- Renal failure or chronic kidney disease with GFR ≤30 ml/min or MDRD GFR ≤30 ml/min per 1.73m2 (and serum creatinine ≥2.5 mg/dL within 30 days of index procedure);
- Physician does not believe subject is an appropriate candidate for study;
- Previous infra-inguinal intervention in the index limb within 30 days of the planned femoropopliteal intervention
Angiographic Exclusion Criteria:
- Inability to cross lesion/occlusion with a guidewire or re-entry device;
- Inability for the guidewire to re-enter and/or remain in the true lumen prior to enrollment;
- In-stent restenosis of the target lesion, or recognition of any stent (patent or re-stenotic within the femoropopliteal segment of the index limb;
- Aneurysm located in the target vessel or aneurysmal vessel;
- Acute thrombus in the index limb prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Non-randomized
Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects. DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™. Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU. Medtronic IN.PACT® Admiral® DCB will be used after DA. Volcano Visions® PV .014" IVUS catheter required to assess lesion in each procedure. Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required. |
Use of FDA Cleared Directional Atherectomy (DA) Devices.
Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System.
DA followed by DCB will be performed in all enrolled subjects.
FDA Approved Drug Coated Balloon (DCB) Technology.
Medtronic IN.PACT® Admiral® DCB will be used after DA.
It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
Lesion IVUS assessment using the Volcano Visions® PV .014"
IVUS catheter will be required in all cases.
Only FDA approved nitinol stents can be used if provisional stenting is required.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Patency
Time Frame: One year
|
One-year primary patency (PSVR ≤2.4) and freedom from CD-TLR in subjects with long, moderate and severely calcified symptomatic femoropopliteal arterial stenoses and occlusions after treatment with DA+DCB.
|
One year
|
Freedom from MAE
Time Frame: One month
|
Freedom from (MAEs) defined as freedom from flow-limiting dissections (D-F), vessel perforations, unplanned amputation, intra-procedure distal athero-embolization and clinically-driven TVR in subjects with long, moderate and severely calcified femoropopliteal lesions and occlusions through 30 day follow up.
|
One month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Success
Time Frame: Post Index Procedure
|
Device Success: ≤ 30% residual stenosis after completion of directional atherectomy procedure (stand-alone) as assessed by the angiographic core lab.
|
Post Index Procedure
|
Procedural Success
Time Frame: Post Index Procedure
|
Procedural Success: ≤30% residual stenosis after completion of the directional atherectomy procedure and DCB as assessed by the angiographic core lab.
|
Post Index Procedure
|
IVUS
Time Frame: Post Index Procedure
|
Core lab assessed correlation between IVUS metrics of luminal diameter, change in plaque area and luminal gain pre- and post-atherectomy, and angiographic core lab assessment of pre- and post-percent diameter stenosis (%DS) and the extent of vascular calcification will be determined
|
Post Index Procedure
|
PACCS scoring and related procedural complications
Time Frame: 1 month
|
The association of moderate and severe calcification as defined by the Peripheral Arterial Calcium Scoring System (PACSS) and the change in %DS, procedure related complications (residual stenosis ≥50%, vessel recoil and/or high-grade dissections requiring use of adjunct technologies) visual quantification of embolic material in the distal protection device and MAEs through 30-days will be assessed
|
1 month
|
Directional Atherectomy
Time Frame: Post Index Procedure
|
Directional Atherectomy device specific metrics of total directional atherectomy time as a function of lesion length, lesion morphology, and total procedure time.
|
Post Index Procedure
|
Major Adverse Events thru 24 months
Time Frame: 24 months
|
Major adverse events through 24-months defined as composite clinically-driven target lesion revascularization (CD-TVR) defined as any re-intervention within the target vessel due to symptoms associated with a drop from post-intervention ABI/TBI >20% or >0.15, major unplanned amputation of the treated limb, and all-cause mortality post 30 day follow up through 2 year follow up.
|
24 months
|
Post procedure TVR
Time Frame: 6, 12, 24 months
|
TVR within 6, 12, 24 months post index procedure
|
6, 12, 24 months
|
CD-TLR post procedure
Time Frame: 6, 12, 24 months
|
TLR within 6, 12, 24 months post index procedure
|
6, 12, 24 months
|
Time to CD-TLR thru 24 months post procedure
Time Frame: 24 months
|
Time to first clinically-driven target lesion revascularization (TLR) through 24 months post-index procedure
|
24 months
|
Major target limb amputation post procedure
Time Frame: 6, 12, 24 months
|
Major target limb amputation within 6, 12, 24 months post index procedure
|
6, 12, 24 months
|
Thrombosis- target lesion post procedure
Time Frame: 6, 12, 24 months
|
Thrombosis at the target lesion site within 6, 12, 24 months post index procedure
|
6, 12, 24 months
|
Primary sustained clinical improvement
Time Frame: 6, 12, 24 months
|
Primary sustained clinical improvement: An improvement shift in the Rutherford classification of at least one class in amputation- and TVR-free surviving subjects at 6, 12, 24 months post procedure
|
6, 12, 24 months
|
Secondary sustained clinical improvement
Time Frame: 6, 12, 24 months
|
Secondary sustained clinical improvement: An improvement shift in the Rutherford classification of at least one class including the need for clinically-driven TVR in amputation-free surviving subjects at 6, 12, 24 months post index procedure
|
6, 12, 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Krishna Singh, MD, VIVA Physicians, Inc.
Publications and helpful links
General Publications
- Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006 Aug 15;114(7):688-99. doi: 10.1161/CIRCULATIONAHA.105.593442. No abstract available.
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007 Jun;26(2):81-157. No abstract available.
- Goodney PP, Travis LL, Nallamothu BK, Holman K, Suckow B, Henke PK, Lucas FL, Goodman DC, Birkmeyer JD, Fisher ES. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):94-102. doi: 10.1161/CIRCOUTCOMES.111.962233. Epub 2011 Dec 6. Erratum In: Circ Cardiovasc Qual Outcomes. 2012 May;5(3):e27.
- McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014 Aug;7(8):923-33. doi: 10.1016/j.jcin.2014.05.006.
- Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, Shammas NW, Clair D; DEFINITIVE Ca(+)(+) Investigators. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca(+)(+) trial. Catheter Cardiovasc Interv. 2014 Aug 1;84(2):236-44. doi: 10.1002/ccd.25384. Epub 2014 Feb 5.
- Yazdani SK, Pacheco E, Nakano M, Otsuka F, Naisbitt S, Kolodgie FD, Ladich E, Rousselle S, Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. 2014 Jan 1;83(1):132-40. doi: 10.1002/ccd.24995. Epub 2013 Jul 3.
- Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Muller-Hulsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24.
- Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015 Feb 3;131(5):495-502. doi: 10.1161/CIRCULATIONAHA.114.011004. Epub 2014 Dec 3.
- Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen DJ, Wang H, Hasenbank MS, Jaff MR; IN.PACT SFA Trial Investigators. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. J Am Coll Cardiol. 2015 Dec 1;66(21):2329-2338. doi: 10.1016/j.jacc.2015.09.063. Epub 2015 Oct 14.
- Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008 Feb 14;358(7):689-99. doi: 10.1056/NEJMoa0706356.
- Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum In: Circulation. 2008 Oct 14;118(16):e670.
- Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, Eschenbach G, Hartmann H, Lange C, Schnorr B, Stiepani H, Zoccai GB, Hanninen EL. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012 Dec;5(6):831-40. doi: 10.1161/CIRCINTERVENTIONS.112.971630. Epub 2012 Nov 27.
- Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014 Jan;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022.
- Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, d'Adamo A, Salvatori FM. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014 Aug;37(4):898-907. doi: 10.1007/s00270-014-0904-3. Epub 2014 May 9.
- Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014 May 1;83(6):E212-20. doi: 10.1002/ccd.25387. Epub 2014 Feb 10.
- Tepe G, Beschorner U, Ruether C, Fischer I, Pfaffinger P, Noory E, Zeller T. Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease: Predictors of Outcome With a Special Emphasis on Calcium. J Endovasc Ther. 2015 Oct;22(5):727-33. doi: 10.1177/1526602815600156. Epub 2015 Aug 6.
- Cioppa A, Stabile E, Popusoi G, Salemme L, Cota L, Pucciarelli A, Ambrosini V, Sorropago G, Tesorio T, Agresta A, Biamino G, Rubino P. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med. 2012 Jul-Aug;13(4):219-23. doi: 10.1016/j.carrev.2012.04.007. Epub 2012 May 25.
- Rocha-Singh KJ, Sachar R, DeRubertis BG, Nolte-Ernsting CCA, Winscott JG, Krishnan P, Scott EC, Garcia LA, Baeriswyl JL, Ansel G, Rosenfield K, Zeller T; REALITY Investigators. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study. Catheter Cardiovasc Interv. 2021 Sep;98(3):549-558. doi: 10.1002/ccd.29777. Epub 2021 Jun 3.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VIVA-CLIN-2016-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
Clinical Trials on Medtronic HawkOne® or TurboHawk™
-
Ohio State UniversityRecruitingDegenerative Disc Disease | Spondylolisthesis | Osteophyte | Spinal Canal Stenosis | Bony Growth FormationUnited States
-
Catharina Ziekenhuis EindhovenRecruitingRefractory Angina Pectoris | Spinal Cord StimulationNetherlands
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Deutsches Herzzentrum MuenchenRecruitingCerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable ValvesGermany
-
Medical University of GrazNot yet recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedPost-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccinePertussis | Tetanus | Diphtheria | PoliomyelitisGermany
-
Kantonsspital Winterthur KSWAbbott; Cantonal Hospital of St. GallenActive, not recruitingPeripheral Arterial DiseaseSwitzerland, Spain
-
Sunnybrook Health Sciences CentreRecruitingPancreatic InsufficiencyCanada
-
GenmabAbbVieActive, not recruitingDiffuse Large B-cell LymphomaKorea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States